Ortataxel
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard | 100.158.836 |
Chemical and physical data | |
Formula | C44H57NO17 |
Molar mass | 871.930 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ortataxel is a drug used in chemotherapy. As of June 2009[update], Spectrum Pharmaceuticals has the drug in a Phase 2 clinical trial.[1]
References
- ^ Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M (May 2019). "Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma". Journal of Neuro-Oncology. 142 (3): 455–462. doi:10.1007/s11060-019-03116-z. PMID 30726533. S2CID 59606955.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- Articles containing potentially dated statements from June 2009
- All articles containing potentially dated statements
- Mitotic inhibitors
- Benzoate esters
- Carbamates
- Secondary alcohols
- Lactones
- Acetate esters
- Taxanes
- All stub articles
- Antineoplastic and immunomodulating drug stubs